LAVA Therapeutics NV (LAVA Therapeutics NV) Common Stock : $3.72 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Common Stock?

LAVA Therapeutics NV's quarterly common stock stayed the same from Sep. 2023 ($3.72 Mil) to Dec. 2023 ($3.72 Mil) and stayed the same from Dec. 2023 ($3.72 Mil) to Mar. 2024 ($3.72 Mil).

LAVA Therapeutics NV's annual common stock increased from Dec. 2021 ($3.65 Mil) to Dec. 2022 ($3.72 Mil) but then stayed the same from Dec. 2022 ($3.72 Mil) to Dec. 2023 ($3.72 Mil).

LAVA Therapeutics NV Common Stock Historical Data

The historical data trend for LAVA Therapeutics NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Common Stock Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

3.65

3.72

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial													3.72	3.72	3.72	3.72	3.72

LAVA Therapeutics NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.